Kenya - English - Pharmacy and Poisons Board

martin dow limited plot no. 37, sector 19, korangi industrial area, - empagliflozin 10mg - tablet - empagliflozin 10mg - empagliflozin

Kenya - English - Pharmacy and Poisons Board

martin dow limited plot no. 37, sector 19, korangi industrial area, - empagliflozin 25mg - coated tablet - empagliflozin 25mg - empagliflozin

Kenya - English - Pharmacy and Poisons Board

empagliflozin inn 10mg - coated tablet - empagliflozin inn 10mg - empagliflozin

Kenya - English - Pharmacy and Poisons Board

empagliflozin inn 25mg - coated tablet - empagliflozin inn 25mg - empagliflozin

Zimbabwe - English - Medicines Control Authority

cipla ltd - empagliflozin; metformin hydrochloride - tablet, coated; oral - 5; 1000mg

Zimbabwe - English - Medicines Control Authority

cipla ltd - empagliflozin; metformin hydrochloride - tablet, coated; oral - 10; 1000mg

Zimbabwe - English - Medicines Control Authority

cipla ltd - empagliflozin; metformin hydrochloride - tablet, coated; oral - 12.5; 1000mg

Zimbabwe - English - Medicines Control Authority

cipla ltd - empagliflozin; metformin hydrochloride - tablet, coated; oral - 25; 1000mg

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 10mg;  ;   - film coated tablet - 10 mg - active: empagliflozin 10mg     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 02b38190 - type 2 diabetes mellitus glycaemic control: jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: monotherapy - when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. add-on combination therapy - in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see further information in section 5.1).

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - empagliflozin 25mg;  ;   - film coated tablet - 25 mg - active: empagliflozin 25mg     excipient: colloidal silicon dioxide croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow 02b38190 - type 2 diabetes mellitus glycaemic control: jardiance is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults and children aged 10 years and above as: monotherapy - when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance. add-on combination therapy - in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see further information in section 5.1).